New cancer clinical trial: Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer

Published on: April 20, 2018 at 12:00PM
Condition:   Bladder Cancer
Intervention:   Drug: Pembrolizumab (MK-3475)
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
Not yet recruiting
https://ift.tt/2qOrw70